Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 3 years ago

Possible Interaction: Cisplatin and Genistein

supplement:

Genistein

Research Papers that Mention the Interaction

The superoxide generation increased by cisplatin was inhibited by staurosporine, an inhibitor of protein kinase C, but was rather enhanced by genistein , an inhibitor of protein tyrosine kinase.
Physiological chemistry and physics and medical NMR  •  2000  |  View Paper
The objective of the present study was to explore the function of genistein , a soy-derived isoflavone, in enhancing the inhibitory effect of cisplatin on HCC cell proliferation and on tumor recurrence and metastasis in nude mice after curative hepatectomy.
Asian Pacific journal of cancer prevention : APJCP  •  2013  |  View Paper
Genistein acts synergistically with drugs such as tamoxifen, cisplatin , 1,3-bis 2-chloroethyl-1-nitrosourea (BCNU), dexamethasone, daunorubicin and tiazofurin, and with bioflavonoid food supplements such as quercetin, green-tea catechins and black-tea thearubigins.
Advances in experimental medicine and biology  •  2004  |  View Paper
Our former research showed that GEN interfered with the anti-tumor effects of cisplatin (CIS) in breast cancer MCF-7 (ERα+/ERβ−) cells.
Molecular and Cellular Biochemistry  •  2019  |  View Paper
GEN treatment provoked an increase in cell viability in MCF‐7 cells and in the antioxidant enzymes protein levels in combination with the cytotoxic agents, decreasing ROS production ( CDDP + GEN and TAM+GEN) and autophagy (TAM + GEN) or apoptosis (CDDP + GEN and TAM + GEN).
Moreover GEN treatment enhanced the cell cycle S phase entry in CDDP+GEN‐ and TAM + GEN‐treated MCF‐7 cells and, in the case of CDDP + GEN, increased the proportion of cells in the G2/M phase and decreased it in the subG0/G1 phase.
Journal of cellular biochemistry  •  2016  |  View Paper
In micromolar concentrations (0.1-10 μM) genistein decreased the cytotoxic effects of cisplatin and tamoxifen.
It is shown that the half maximal inhibitory concentration (IC50) value of genistein (0.2 mM) for the growth inhibition of HeLa cells is at least ten times higher than that one of tamoxifen and cisplatin --drugs, used in cervical cancer treatment.
Biofizika  •  2015  |  View Paper
Although both LH1 and LH2 were found to be less active than cisplatin against the tumour models, they produced synergistic outcomes in combination with genistein.
Anticancer research  •  2015  |  View Paper
In addition, genistein enhanced the anti-proliferative effect of cisplatin on H446 cells.
Tumor Biology  •  2013  |  View Paper
Co-treatment with CIS and 10−4M GEN resulted in additive effects.
Our data provide evidence that GEN in the absence of E2, a situation which occurs in postmenopausal women, directly affects the anti-tumor activity of cytostatic drugs like CIS.
Archives of Toxicology  •  2013  |  View Paper
Collectively, our results clearly suggest that genistein pretreatment inactivates NF-kappaB and may contribute to increased growth inhibition and apoptosis induced by cisplatin , docetaxel, and doxorubicin in prostate, breast, lung, and pancreatic cancer cells.
We found that 15 to 30 micromol/L genistein combined with 100 to 500 nmol/L cisplatin , 0.5 to 2 nmol/L docetaxel, or 50 ng/mL doxorubicin resulted in significantly greater inhibition of cell growth and induction of apoptosis compared with either agent alone.
Cancer research  •  2005  |  View Paper
Show More